Linton, Okechukwu R.Moore, Michael G.Brigance, Joseph S.Summerlin, Don-JohnMcDonald, Mark W.2015-11-192015-11-192015-01Linton, O. R., Moore, M. G., Brigance, J. S., Summerlin, D.-J., & McDonald, M. W. (2015). Proton therapy for head and neck adenoid cystic carcinoma: Initial clinical outcomes. Head & Neck, 37(1), 117–124. http://doi.org/10.1002/hed.23573https://hdl.handle.net/1805/7511Background The purpose of this study was to report outcomes of proton therapy in head and neck adenoid cystic carcinoma. Methods We conducted a retrospective analysis of 26 patients treated between 2004 and 2012. Twenty patients (77%) had base of skull involvement; 19 (73%) were treated for initial disease and 7 (27%) for recurrent disease. Twenty patients were treated postoperatively, 6 after biopsy alone and 24 had positive margins or gross residual disease. Median dose delivered was 72 Gy (relative biological effectiveness [RBE]). Results Median follow-up was 25 months (range, 7–50 months). The 2-year overall survival was 93% for initial disease course and 57% for recurrent disease (p = .19). The 2-year local control was 95% for initial disease and 86% for recurrent disease (p = .48). The 2-year distant metastatic rate was 25%. Late toxicity of grade 0 or 1 was seen in 17 patients, grade 2 in 5, grade 3 in 2, grade 4 in 1, and grade 5 in 1. Conclusion Initial outcomes of proton therapy are encouraging. Longer follow-up is required.en-USPublisher Policyadenoid cystic carcinomaproton therapyhead and neckArticle